Synthesis and Trypanocidal Properties of New Coumarin-Chalcone Derivatives

Saleta Vazquez-Rodriguez*, Roberto Figueroa Guíñez*, Maria João Matos*, Claudio Olea-Azar*, Juan Diego Maya*, Eugenio Uriarte*, Lourdes Santana* and Fernanda Borges*

1 CIQUP/Department of Chemistry and Biochemistry, Faculty of Sciences, University of Porto, Rua Campo Alegre 687, 4169-007 Porto, Portugal
2 Department of Inorganic and Analytical Chemistry, Faculty of Chemical and Pharmaceutical Science, University of Chile, Casilla 233, Santiago, Chile
3 Departamento of Molecular and Clinical Pharmacology, Faculty of Medicine, University of Chile, Santiago, Chile
4 Department of Organic Chemistry, Faculty of Pharmacy, University of Santiago de Compostela, Campus Vida s/n, 15782, Santiago de Compostela, España

Abstract

With the aim of finding new chemical entities based on coumarin and chalcone scaffolds, new hybrid compounds 2-5 were designed and synthesized. The trypanocidal activity of these compounds was tested against the epimastigote, trypomastigote and amastigote stages of the Trypanosoma cruzi parasite. Cytotoxicity assays were also performed in RAW 264.7 and VERO cells. Compound 5 presented the highest trypanocidal activity of the series, with trypanocidal values higher than Nifurtimox for the trypomastigote and epimastigote stages, but presenting cytotoxic effects in the mammalian cells. A SAR study suggested that methoxy substitution at positions 2' and 5' in the designed scaffold seemed to be a key feature for the trypanocidal activity. Therefore, the coumarin-chalcone scaffold can be taken into account for further lead optimization and design new and more effective trypanocidal compounds.

Keywords: Chagas disease; Chalcone; Coumarin; Cytotoxicity; Natural products; Structure-activity relationship; Trypanosoma cruzi

Introduction

American Trypanosomiasis or Chagas disease is a chronic parasitosis, caused by the Kinetoplastid parasite Trypanosoma cruzi (T. cruzi), which has afflicted humanity since its earliest presence in the New World [1] but whose true nature as an infectious disease was just discovered a hundred years ago by Carlos Chagas in Minas Gerais, Brazil. An estimated 10 million people are infected with T. cruzi worldwide, mostly in Latin America, and more than 25 million people are at risk for the disease. The parasite’s biological cycle includes three fundamental forms characterized by the relative positions of the flagellum, kinetoplast, and nucleus [2]: 1) Trypomastigotes: Constitute the infecting form, and are found in mammalian blood and the hindgut of triatomine bugs; they do not multiply. In mammals they are the disseminators of blood-borne infection. 2) Epimastigotes: They represent the parasite’s multiplicative form in the triatomid’s intestine, and are the predominant form in culture. For this reason, it is the most commonly form used in biochemical studies. 3) Amastigotes: They multiply by means of binary fission inside mammalian host cells, producing their rupture, and liberating trypomastigotes into the bloodstream that can once again invade any nucleated cell. They can be grown in culture in muscle cells, fibroblasts, and macrophages among others [3].

Present treatment for Chagas disease relies on two drugs, Nifurtimox and Benznidazole discovered empirically more than three decades ago [4,5]. These drugs are effective for acute infections, but their use for chronic patients remains controversial [6]. Furthermore, studies of the mechanisms of action indicated that their antiparasitic activity is linked to mammalian host toxicity [7]. The efficacy of these drugs also depends on the susceptibility of T. cruzi strains and resistance to benznidazole has been reported [8]. Therefore, the discovery of new and more effective drugs that can be well tolerated and safer, is a topic of major interest [9].

Coumarins are a family of natural and/or synthetic compounds with different pharmacological activities [10,11], being one of them the antiparasitic activity [12,13]. Some coumarins proved to be important molecules in the regression of the described pathology. Previous studies described that they act by inhibiting GAPDH (enzyme commission number 1.2.1.12), an important protein present in the trypanosomatids glycolytic pathway [14]. It has also been described that some coumarin derivatives are potent growth inhibitors of Leishmania amazonensis causing important changes in the parasite’s ultrastructure such as mitochondrial swelling with concentric membranes in the mitochondrial matrix and intense exocytic activity in the region of the flagellar pocket [15].

On the other hand, chalcones are another family of natural and/or synthetic compounds that present a wide range of biological activities [16,17]. Some chalcones with important antiparasitic activity have been described [18,19]. Previous studies have shown that licochalcone A, present in the Chinese licorice root, altered the ultrastructure and function of the mitochondria of Leishmania species without damaging the organelles of macrophages or the phagocytic function of these cells [20]. It has also been described that antiparasitic activity of some oxygenated chalcones might be the result of interferences with function of the parasite mitochondria [21].

Materials and Method

Chemistry

Melting points were determined using a Reichert Kofler thermopan or in capillary tubes on a Büchi 510 apparatus and are uncorrected. 1H and 13C NMR spectra were recorded on a Bruker AMX spectrometer at 250 and 75.47 MHz, respectively, using TMS as internal standard (chemical shifts in δ values, J in Hz). Mass spectra were obtained using a Hewlett-Packard 5988A spectrometer. Elemental analyses were performed using a Perkin-Elmer 240B microanalyser and were within ± 0.4% of calculated values in all cases. Silica gel (Merck 60, 230–00
mesh) was used for flash chromatography (FC). Analytical thin layer chromatography (TLC) was performed on plates precoated with silica gel (Merck 60 F254, 0.25 mm). The purity of the compounds was found to be higher than 95%.

Preparation of 3-acetylcoumarin (1) [22]: A mixture of salicylaldehyde (1 eq.), ethyl acetocetate (1 eq.) and a few drops of piperidine were mixed for 30 min. at room temperature without any solvent. Reaction was neutralized with HCl (dil.) and finally the product was isolated by filtration. The final compound was then recrystallized in EtOH.

General procedure for the synthesis of 3-(3-aryl)acryloylcoumarin (2-5): 3-Acetylcoumarin (1, 1 mmol) and the conveniently substituted aromatic aldehyde (1.1 mmol) were dissolved in EtOH (3 mL) and a catalytic amount of piperidine (0.05 mL) was added. The reaction mixture was stirred for 4-12 hours under reflux. After completion of reaction (followed by TLC), the solvent was evaporated under vacuum and the dry residue was purified by Flash Chromatography using hexane-acetone (8:2) as eluent to give the desired products 2-5.

(E)-3-(3-(4-Methoxyphenyl)acryloyl)coumarin (3): Yield 91%. Mp: 192-194ºC. H NMR (250 MHz, CDCl3) δ ppm 8.37 (s, 1H), 8.00 (d, J = 15.8 Hz, 1H), 7.72 (d, J = 15.7 Hz, 1H), 7.55 - 7.39 (m, 2H), 7.27 - 7.11 (m, 2H), 6.36 (dd, J = 8.6, 2.4 Hz, 1H), 6.29 (d, J = 2.4 Hz, 1H), 3.73 (s, 3H), 3.69 (s, 3H). 13C NMR (75 MHz, CDCl3) δ ppm 186.7, 163.4, 160.7, 159.3, 151.1, 147.3, 140.7, 133.8, 131.1, 129.8, 126.0, 124.8, 121.9, 118.7, 117.1, 116.6, 105.5, 98.3, 55.5, 55.5. MS m/z (%): 337 ([M+H]+, 13), 306 ([M]+, 100), 277 (18), 161 (91), 133 (39), 89 (51).

(E)-3-(3-(4-Methoxyphenyl)acryloyl)coumarin (4): Yield 96%. Mp: 190-192ºC. 1H NMR (250 MHz, CDCl3) δ ppm 8.38 (s, 1H), 8.05 (d, J = 15.8 Hz, 1H), 7.65 (d, J = 15.7 Hz, 1H), 7.56 - 7.39 (m, 2H), 7.27 - 7.12 (m, 2H), 7.01 (s, 1H), 6.33 (s, 1H), 3.78 (s, 3H), 3.74 (d, J = 1.7 Hz, 6H). 13C NMR (75 MHz, CDCl3) δ ppm 186.6, 154.9, 151.1, 153.0, 147.4, 143.3, 140.3, 133.9, 129.9, 126.9, 126.9, 124.9, 121.9, 118.7, 117.1, 116.6, 105.5, 98.3, 85.6, 55.5, 55.5. MS m/z (%): 337 ([M]+), 246, 336 ([M]+), 100, 305 (42), 191 (53), 145 (41), 137 (29), 92 (18), 77 (15).

(E)-3-(3-(4-Methoxyphenyl)acryloyl)coumarin (5): Yield 83%. Mp: 114-115ºC. 1H NMR (250 MHz, CDCl3) δ ppm 8.54 (s, 1H), 8.18 (d, J = 15.8 Hz, 1H), 7.93 (d, J = 15.8 Hz, 1H), 7.73 - 7.57 (m, 2H), 7.44 - 7.28 (m, 2H), 7.21 (d, J = 3.0 Hz, 1H), 7.00 - 6.79 (m, 2H), 3.87 (s, 3H), 3.81 (s, 3H). 13C NMR (75 MHz, CDCl3) δ ppm 186.8, 159.3, 155.2, 153.6, 153.5, 147.7, 140.2, 134.0, 129.9, 125.7, 124.9, 124.5, 124.3, 118.6, 118.2, 116.6, 112.4, 56.1, 55.8. MS m/z (%): 337 ([M]+), 10, 336 ([M]+, 29), 306 (34), 305 (100), 173 (23), 89 (26).

Biological assays

Epimastigote viability study: Trypanocidal activity was evaluated against the T. cruzi epimastigote stage (clone Dm28c). It was measured through the MTT assay [23] using 0.22 mg mL phenazine metosulfate (as electron carrier). T. cruzi epimastigotes Dm28c strain, from our own collection (Programa de Farmacología Molecular y Clínica, Facultad de Medicina, Universidad de Chile) were grown at 28ºC in Diamond’s monophasic medium, as reported earlier but replacing blood by 4 µM hemin [24]. Fetal calf serum was added to a final concentration of 5 %. In this colorimetric were dissolved in DMSO and were added to 3 x 106 parasites mL-1 at 10 µM final concentrations in RPMI 1640 culture medium for 24 h at 28ºC. DMSO final concentration was less than 0.1% v/v. Likewise, nifurtimox was added as positive control. Tetrazolium salt was added at a final concentration of 0.5 mg mL-1, incubated at 28ºC for 4 h and then solubilized with 10% sodium dodecyl sulfate/0.1 mM HCl and incubated overnight. After incubation time, it was determined the number of viable parasites by absorbance measures at 570 nm in a multi-well plate reader (Asys Expert Plus©, Austria). Untreated parasites were used as controls (100% of viability). Results are reported in Table 1 as the percentage of non-viable epimastigotes regarding the control.

Trypomastigote viability study: Cell culture and in vitro infection with T. cruzi (Dm28c strain) trypomastigote: Vero cells were infected with Dm28c trypomastigotes at a 1:3 (cell:parasite) ratio. T. cruzi trypomastigotes were initially obtained from primary cultures of peritoneal macrophage from chagasic mice. Vero cells were cultured in 5% fetal bovine serum supplemented RPMI 1640 medium in humidified air with 5 % CO2 at 37ºC. Vero cell cultures were then infected with trypomastigotes were incubated at 37ºC in humidified air and 5% CO2, for 5-7 days. After that time, the culture medium was collected, centrifuged at 500 g for 5 min, and the trypomastigote-containing pellet was re-suspended in free serum RPMI 1640 and penicillin-streptomycin at a final density of 1x10⁷ parasites/mL. Trypomastigote viability assays were performed using the MTT reduction method as described previously. 1x10⁷ parasites/mL were incubated in free serum RPMI 1640 culture medium at 37ºC during 24 h with or without the studied compounds. An aliquot of the parasite suspension was extracted and incubated in a 96-flat bottom well plate and MTT was added at 0.5 mg/mL final concentration and using 0.22 mg mL-1 phenazine metosulfate (as electron carrier), incubated at 28ºC for 4 h and then made soluble with 10% SDS-0.1 mM HCl and incubated overnight. Formazan formation was measured at 570 nm, with reference wavelength at 690 nm, in a multi-well plate reader (Asys Expert Plus©, Austria). Untreated parasites were used as controls (100% of viability). Results are reported in Table 1 as the percentage of non-viable parasites regarding the control.

Amastigote viability study: Amastigotes were obtained with the same technique [23] used for trypomastigotes, but Vero cells were infected with Dm28c trypomastigotes at a 1:10 (cell:parasite) ratio, which induces cell rupture and release of amastigotes into the medium after 5 days. The culture medium was collected, centrifuged at 500 g for 5 min, and the amastigote-containing pellet was re-suspended in free serum RPMI 1640 and penicillin-streptomycin at a final density of 2x10⁷ amastigotes/mL. Amastigote viability assays were performed using the MTT reduction method as described previously. 2x10⁷ parasites/mL were incubated in free serum RPMI 1640 culture medium at 37ºC during 24 h with or without the compound 4. An aliquot of the parasite suspension was extracted and incubated in a 96-flat bottom well plate and incubated at 28ºC during 4 h and then made soluble with 10% SDS-0.1 mM HCl and incubated overnight. Formazan formation was measured at 570 nm, with reference wavelength at 690 nm, in a multi-well plate reader (Asys Expert Plus©, Austria). Untreated parasites were used as controls (100% of viability). Results are reported in Table 1 as the percentage of non-viable parasites regarding the control.

Cytotoxicity assay: Green Monkey (Cercopithecus aethiops) renal fibroblast like cells (VERO cells (ATCC® CCL-81)) were grown in RPMI medium enriched with 5% fetal bovine (FBS) serum and antibiotics (penicillin–streptomycin). Cells were grown at 37ºC in a
humid atmosphere at 5% CO₂ for 96 h, replacing the medium every 24 h [25].

The effect of drug treatments on RAW 264.7 cells was evaluated through the MTT assay as viability test [26]. Briefly, 10 µL of 5 mg/mL tetrazolium dye (MTT; 3(4,5- dimethylthiazol-2-yl]-2,5- diphenyltetrazolium bromide) plus 0.22 mg/mL phenazine metosulfate (electron carrier), were added to each well containing RAW 264.7 cell culture in 100 µL RPMI 1640 without phenol red.

Compounds under study, dissolved in DMSO, were added to the culture media. DMSO final concentration was less than 0.25 % v/v. After incubation for 4 h at 37°C, the generated water insoluble formazan dye was dissolved by addition of 100 µL of 10% w/v SDS in 0.01M HCl. The plates were further incubated overnight at 37°C, and optical density (OD) of the wells was determined using a microplate reader (Asys Expert Plus®, Austria) at 570 nm. Under these conditions, the OD is directly proportional to the viable cell number in each well. All experiments were performed at least three times and data are shown as means and their standard deviations from triplicate cultures. Results are reported as the percentage of non-viable VERO or RAW 264.7 cells regarding the control.

Results and Discussions

Based on the previously mentioned features of coumarins and chalcones, and in our experience with 3-amido and 3-benzoyl coumarins as potential trypanocidal agents, [12,27] we decided to design and synthesize new coumarin-chalcone hybrid compounds (Figure 1) with the aim of finding new chemical entities with trypanocidal activity.

Compounds 2-5 were efficiently synthesized according to the protocol outlined in Figure 2. Compounds were prepared in a two-step synthetic route. In the first step the 3-acetylcoumarin (1) was prepared with 93% yield by a Knoevenagel reaction using salicylaldehyde and ethyl acetoacetate without solvent and employing piperidine in catalytic amount at room temperature [22]. The last step involves a Claisen-Schmidt condensation in EtOH, using piperidine as base, mixed with the corresponding aromatic aldehydes under reflux to afford the desired final compounds 2-5 in good to excellent yields (60-96%).

It is known that the activity against one form of the parasite life cycle does not ensure similar activities against the others. Morphologic changes occur during the transformation between cycle. The sensibility of the different forms to the drugs is, therefore, modified [28].

Compounds 2-5 were studied in the epimastigote, trypomastigote stages of the T.cruzi parasite and compound 5 was additionally studied in the amastigote stage. Results are presented in Table 1.

Compounds were generally more active against the trypomastigote stage, which is the infective form in the mammalian host, since it is
Citation: Rodriguez SV, Guímez RF, Matos MJ, Azar CO, Maya JD, et al. (2015) Synthesis and Trypanocidal Properties of New Coumarin-Chalcone Derivatives. Med chem 5: 173-177. doi:10.4172/2161-0444.1000260

The results of the means of three different experiments with a SD less than 10% in all cases.

| parasite stage | IC50 (µM) |
|----------------|-----------|
| Nifurtimox     | 17.4 ± 5.1|
| Compound 5     | 46.8 ± 3.7|
| Epimastigote   | 10.0 ± 0.4|
| Trypomastigote | 18.6 ± 2.6|
| Amastigote     | 2.9 ± 0.1 |

The results are the means of two different experiments with a SD less than 10% in all cases. 

* IC50 concentration that produces 50% of inhibitory effect.

Table 2: IC50 values for compound 5 and Nifurtimox in different parasite stages.

| Cell line   | IC50 (µM) |
|-------------|-----------|
| RAW 264.7   | 263.4 ± 25.4|
| Nifurtimox  | 61.1 ± 0.5 |
| Compound 5  | 56.8 ± 5.4 |
| VERO        | >100 |

The results are the means of two different experiments with a SD less than 10% in all cases. 

* IC50 concentration that produces 50% of inhibitory effect.

Table 4: IC50 in mammalian cell lines.

the disseminator of blood-borne infection. The most active compound of the series was compound 5. At the lowest concentration tested (10 µM), compound 5 was twice as active as Nifurtimox against the trypomastigote stage of the parasite.

A structure-activity relationship study (SAR) showed that compound 2, bearing just one methoxy group at 4’ position was the less active compound of the series. When one additional methoxy group was added to the molecule at positions 2’ (compound 3) or even two methoxy groups at positions 2’ and 5’ (compound 4), the trypanocidal activity increases compared to compound 2. However, when there was no methoxy group at position 4, and only two methoxy groups were positioned at 2’ and 5’ (compound 5), the trypanocidal activity increased significantly and this fact could indicate that methoxy substitution at positions 2’ and 5’, and no substitution at position 4’ was a key feature for the trypanocidal activity of this scaffold.

Since compound 5 presented the most promising trypanocidal activity, its IC50 (µM) against the three parasite stages was calculated and compared with the IC50 values for the current drug Nifurtimox. Results are shown in Table 2. It was observed that compound 5 (IC50 = 2.6 µM) was 4 times more active than Nifurtimox (IC50 = 10.0 µM) against the trypomastigote stage parasite. In addition, against the amastigote stage, compound 5 was also more that 6 times more active than Nifurtimox (IC50 = 2.9 and 18.9 µM, respectively)

Cytotoxicity assays, in murin RAW 264.7 macrophages and VERO cells were performed, and results are summarized in Table 3. It was observed that compounds 2-4 were less cytotoxic at low concentration (10 µM) than compound 5, which resulted cytotoxic at 10 and 100 µM for RAW 264.7, and it was especially cytotoxic against VERO cells at the highest concentration tested.

Compound 5 was the most cytotoxic compound, and in order to quantify the sensibility against the two mammalian cell lines the IC50 (µM) was calculated and compared to Nifurtimox. Results are presented in Table 4.

The IC50 values in parasitic stages and in mammalian cell showed that compound 5 presented the most promising trypanocidal activity, but it was also toxic in mammalian cell lines.

Conclusion

In conclusion, a new series of coumarin-chalcone hybrid compounds was design and synthesized as trypanocidal agents. Compounds were tested against the epimastigote, trypomastigote and amastigote stages of the T. cruzi parasite. All compounds were more active against the trypomastigote stage, being the most promising molecule compound 5, which presented IC50 values 4 and 6 times higher than Nifurtimox for the trypomastigote and amastigote stages, respectively. However, compound 5 showed high cytotoxicity values in RAW 264.7 and VERO cells. Methoxy substitution at positions 2’ and 5’ of the designed scaffolds seemed to be a key feature for the trypanocidal activity. Therefore, the coumarin-chalcone scaffold can be taken into account for further lead optimization and design new and more effective trypanocidal compounds.

Acknowledgements

The authors thank the Foundation for Science and Technology (FCT) of Portugal (PEst-C/QUI/UI0091/2013 project) and the FONDECYT (projects 1150175 and 1130189) and Anillo ACT112 (Chile). S.V.R. thanks to the University of Porto for the postdoctoral grant NORTE-07-0124-FEDER-000065. RF gratefully acknowledges CONICYT-Chile for his PhD scholarship (No. 21100132) and his PhD grant (No. 21212574). M.J.M, thanks to the Fundação para a Ciência e Tecnologia (FCT), POPH (Programa Operacional Potencial Humano) and QREN (Quadro de Referência Estratégico Nacional) for the postdoctoral grant (SRFH/ BPDI/85345/2013).

References

1. Aufderheide AC, Salo W, Madden M, Streitz J, Buikstra J, et al. (2004) A 9,000-year record of Chagas' disease. Proc Natl Acad Sci U S A 101: 2034-2039.
2. Prata A (2001) Clinical and epidemiological aspects of Chagas disease. Lancet Infect Dis 1: 92-100.
3. Faundez M, Pino L, Letelier P, Ortiz C, Lopez R, et al. (2005) Buthionine sulfoximine increases the toxicity of nifurtimox and benznidazole to Trypanosoma cruzi. Antimicrob Agents Chemother 49: 126-130.
4. Boiani M, Placenza L, Hernández P, Boiani L, Cerecetto H, et al. (2010) Mode of action of Nifurtimox and N-oxide-containing heterocycles against Trypanosoma cruzi: Is oxidative stress involved? Biochem Pharmacol 79: 1736-1745.
5. Hall BS, Wilkinson SR (2012) Activation of benznidazole by trypanosomal type I nitroreductases results in glyoxal formation. Antimicrob Agents Chemother 56: 115-123.

6. Croft SL, Barrett MP, Urbina JA (2005) Chemotherapy of trypanosomiases and leishmaniasis. Trends Parasitol 21: 508-512.

7. Urbina JA (2010) Specific chemotherapy of Chagas disease: relevance, current limitations and new approaches. Acta Trop 115: 55-68.

8. Andriani G, Chessler AD, Courtemanche G, Burleigh BA, Rodriguez A (2011) Activity in vivo of anti-Trypanosoma cruzi compounds selected from a high throughput screening. PLoS Negl Trop Dis 5: e1298.

9. Gutiérrez B, Muñoz C, Osorio L, Fehér K, Illyés TZ, et al. (2013) Aromatic glycosyl disulfide derivatives: Evaluation of their inhibitory activities against Trypanosoma cruzi. Bioorg Med Chem Lett 23: 3576-3579.

10. Borges F, Roleira F, Milhazes N, Santana L, Uriarte E (2005) Simple coumarins and analogues in medicinal chemistry: occurrence, synthesis and biological activity. Curr Med Chem 12: 887-916.

11. Borges MFM, Roleira FMF, Uriarte E, Santana L (2009) Simple Coumarins: Privileged Scaffolds in Medicinal Chemistry. Front Med Chem 4: 23-85.

12. Guíñez RF, Matos MJ, Vazquez-Rodriguez S, Santana L, Uriarte E, et al. (2013) Synthesis and evaluation of antioxidant and trypanocidal properties of a selected series of coumarin derivatives. Future Med Chem 5: 1911-1922.

13. Reyes-Chilpa R, Estrada-Muniz E, Vega-Avila E, Abe F, Kirjo J, et al. (2008) Trypanocidal constituents in plants: 7. Mammrea-type coumarins. Mem Inst Oswaldo Cruz 103: 431-436.

14. Freitas RF, Prokopczyk IM, Zottis A, Oliva G, Andricopulo AD, et al. (2009) Discovery of novel Trypanosoma cruzi glyceraldehyde-3- phosphate dehydrogenase inhibitors. Bioorg Med Chem 17: 2476-2482.

15. Brenzan MA, Nakamura CV, Prado Dias Filho B, Ueda-Nakamura T, Young MC, et al. (2007) Antileishmanial activity of crude extract and coumarin from Calypomyrtus brasiliense leaves against Leishmania amazonensis. Parasitol Res 10: 715-722.

16. Sahu NK, Balbhadra SS, Choudhary J, Kohli DV (2012) Exploring pharmacological potential of chalcone scaffold: a review. Curr Med Chem 19: 209-225.

17. Singh P, Anand A2, Kumar V3 (2014) Recent developments in biological activities of chalcones: a mini review. Eur J Med Chem 85: 758-777.

18. Lunardi F, Guzelia M, Rodrigues AT, Correa R, Eger-Mangrich I, et al. (2003) Trypanocidal and leishmanicidal properties of substitution-containing chalcones. Antimicrob Agents Chemother 47: 1449-1451.

19. Sinha S, Medihi B, Sehgal R (2013) Chalcones as an Emerging Lead Molecule for Antimalarial Therapy: A Review. J Mod Med Chem 1: 64-77.

20. Zhai L, Blom J, Chen M, Christensen SB, Kharazmi A (1995) The antileishmanial agent licochalcone A interferes with the function of parasite mitochondria. Antimicrob Agents Chemother 39: 2742-2748.

21. Zhai L, Chen M, Blom J, Theander TG, Christensen SB, et al. (1999) The antileishmanial activity of novel oxygenated chalcones and their mechanism of action. J Antimicrob Chemother 43: 793-803.

22. Sugino T, Tanaka K (2001) Solvent-free coumarin synthesis. Chem Lett 30: 110-111.

23. Bisby RH, Brooke R, Navaratnam S (2008) Effect of antioxidant oxidation potential in the oxygen radical absorption capacity (ORAC) assay. Food Chem 108: 1002-1007.

24. Vieites M, Otero L, Santos D, Tolosa J, Figueroa R, et al. (2008) Platinum(II) metal complexes as potential anti-Trypanosoma cruzi agents. J Inorg Biochem 102: 1033-1043.

25. Salas C, Tapia RA, Ciudad K, Armstrong V, Orellana M, et al. (2008) Trypanosoma cruzi: activities of lapachol and alpha- and beta-lapachone derivatives against epimastigote and trypomastigote forms. Bioorg Med Chem 16: 666-674.

26. Mosmann T (1983) Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxicity assays. J Immunol Methods 65: 55-63.

27. Vazquez-Rodriguez S, Figueroa-Guíñez R, Matos MJ, Santana L, Uriarte E, et al. (2013) Synthesis of coumarin–chalcone hybrids and evaluation of their antioxidant and trypanocidal properties. Med Chem Commun 4: 1058-1067.

28. Demoro B, Rossi M, Caruso F, Liebowitz D, Olae-Azar C, et al. (2013) Potential mechanism of the anti-trypanosomal activity of organoncruelium complexes with bioactive thiosaccharinazones. Biof Trace Elem Res 153: 371-381.